Knight Therapeutics Investor Relations Material
Latest events
Q2 2024
Knight Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Knight Therapeutics Inc
Access all reports
Segment Data
Access more data
Revenue by
Geography
Brazil
Argentina
Colombia
Rest of LATAM
Other
Expenses by
Financials
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada and internationally. It offers Impavido (miltefosine), an oral antifungal product for the treatment of visceral, cutaneous, and mucosal leishmaniasis; Macrilen (macimorelin), a growth hormone secretagogue receptor agonist for use in the investigational stimulation testing of adults with adult growth hormone deficiency; Probuphine (buprenorphine) implant for subdermal administration to facilitate remission from opioid use disorder; Neuragen or NeurogesX topical research portfolio consisting of Qutenza (capsaicin 8% patch) for neuropathic pain indication in Canada.
Latest articles
Deere & Company: Shaping the Future of Agriculture Since 1837
Detailing the history of agriculture and Deere & Company, all the way from 1837 to the present day.
25 Oct 2024
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Ticker symbol
GUD
Country
🇨🇦 Canada